Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from ImmunityBio ( (IBRX) ) is now available.
On February 18, 2026, ImmunityBio announced that the European Commission granted conditional marketing authorization for ANKTIVA in combination with BCG to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ, with or without papillary tumors. This decision makes ANKTIVA plus BCG the first authorized immunotherapy in Europe for this high-risk bladder cancer population, where the primary alternative had been radical cystectomy.
The authorization covers all 27 EU member states plus Iceland, Norway and Liechtenstein, expanding ANKTIVA’s reach to 33 countries within four regulatory jurisdictions less than two years after the initial U.S. FDA approval in April 2024. Supported by phase 2/3 trial data showing a 71% complete response rate, durable responses and a favorable safety profile, the move significantly strengthens ImmunityBio’s global commercial footprint in bladder cancer and addresses a major unmet medical need for European patients, while obligating the company to provide ongoing long-term safety and efficacy data to regulators.
The most recent analyst rating on (IBRX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held back primarily by weak financial health—losses, negative equity, and negative operating/free cash flow. Technicals are strong but look overbought, while valuation remains challenging due to negative earnings. Offsetting these risks, recent regulatory approvals and expanded market access are supportive catalysts.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio, Inc. is a commercial-stage immunotherapy company focused on developing and marketing immune-based treatments for cancer. Its lead product, ANKTIVA (nogapendekin alfa inbakicept), is an IL-15 receptor agonist designed to enhance natural killer and T-cell responses, with an initial market focus on non-muscle invasive bladder cancer and expanding indications in oncology across multiple global jurisdictions.
Average Trading Volume: 27,607,555
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.86B
For a thorough assessment of IBRX stock, go to TipRanks’ Stock Analysis page.